A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
|ClinicalTrials.gov Identifier: NCT00300664|
Recruitment Status : Completed
First Posted : March 9, 2006
Last Update Posted : October 13, 2006
About 90% of patients with haemato-oncologic malignancy lose their body muscle mass and also lose weight either due to chemotherapy induced nausea/vomiting or the high catabolic state due to fever, sepsis or chemotherapy. This impacts tremendously on the days in hospital and also on the treatment-related complications. Studies with Human Growth hormone (hGH) have shown that it increases lean body mass in adult patients with AIDS and animal models of cancer. At the same time, in vitro studies have shown that hGH has no effect on tumor cell growth. This study is designed to see if the use of hGH in immunocompromised patients with haematological malignancies prevents the loss of muscle mass and weight loss to some extent.
This will be a blinded 1:1, randomised study including 150 patients whereby the patients will either receive hGH or a placebo. The doctors and the nurses will not know what drug the patient is receiving. Both hGH and the placebo will be given intravenously (if patients are receiving other intravenous antibiotics or haemopoietic support ) or subcutaneously (if platelets are above 20 x 109/L) The treatment will start on the first day of treatment and continue for 6 weeks.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Myelodysplastic Syndrome||Drug: Human Growth hormone||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||July 2002|
|Study Completion Date :||April 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00300664
|Principal Investigator:||Ray Powles, FRCP, FRCPath||Royal Marsden NHS Foundation Trust|